Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIORITIZE Study: Oral Regimens for Hepatitis C
NCT02786537Phase 4Completed
- Sponsor
- University of Florida
- Start
- Jun 2016
- Primary completion
- Jun 2019
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of elbasvir + grazoprevir, Harvoni and Viekira Pak in hepatitis C virus infection (6 arms), sponsored by University of Florida. Primary endpoints: Sustained Virologic Response at 12 Weeks, Patient Reported Outcome: Headache at 12 weeks and 3 more. Started Jun 2016; status: completed.
02
Drugs
elbasvir + grazoprevirHarvoniViekira Pak
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT02786537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02786537.